Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-γ …
M Wysocka, S Newton, BM Benoit, C Introcaso… - Clinical Lymphoma and …, 2007 - Elsevier
Advanced cutaneous T-cell lymphoma (CTCL) is typically associated with a variety of
profound defects of cellular immunity, including depressed dendritic cell numbers and …
profound defects of cellular immunity, including depressed dendritic cell numbers and …
Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell …
M Wysocka, N Dawany, B Benoit… - Leukemia & …, 2011 - Taylor & Francis
Cutaneous T-cell lymphoma (CTCL) is responsive at all stages to immunotherapy. We
determined whether a novel agonist for Toll-like receptor (TLR) 7/8 (3M-007) combined with …
determined whether a novel agonist for Toll-like receptor (TLR) 7/8 (3M-007) combined with …
Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod
DE Spaner, RL Miller, J Mena, L Grossman… - Leukemia & …, 2005 - Taylor & Francis
The identification of clinically relevant, active immunomodulatory agents is important for
developing immunotherapeutic approaches to chronic lymphocytic leukemia (CLL) and …
developing immunotherapeutic approaches to chronic lymphocytic leukemia (CLL) and …
A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice
GM Wiedemann, SJ Jacobi, M Chaloupka… - …, 2016 - Taylor & Francis
ABSTRACT Toll-like receptor 7 (TLR7) agonists are potent immune stimulants able to
overcome cancer-associated immune suppression. Due to dose-limiting systemic toxicities …
overcome cancer-associated immune suppression. Due to dose-limiting systemic toxicities …
TLR7 and TLR8 as targets in cancer therapy
MP Schön, M Schön - Oncogene, 2008 - nature.com
Small-molecule agonists at Toll-like receptor 7 (TLR7) and TLR8 have sparked a vivid
interest in cancer research owing to their profound antitumoral activity. The lead compound …
interest in cancer research owing to their profound antitumoral activity. The lead compound …
Mechanism of action and other potential roles of an immune response modifier.
AA Gaspari - Cutis, 2007 - europepmc.org
Imiquimod (1-[2-methylpropyl]-1H-imidazo [4, 5-c] quinolin-4-amine) is a widely used topical
immune response modifier. This drug was initially developed as an antiviral agent and was …
immune response modifier. This drug was initially developed as an antiviral agent and was …
Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3‐expressing lymphocytes into the skin following treatment with the TLR7‐agonist …
J Wenzel, M Uerlich, O Haller, T Bieber… - Journal of cutaneous …, 2005 - Wiley Online Library
Introduction: Imiquimod (Aldara™) is an immune response modifier approved for the topical
treatment of external genital and perianal warts which can mediate regression of several …
treatment of external genital and perianal warts which can mediate regression of several …
UC‐1V150, a potent TLR 7 agonist capable of activating macrophages and potentiating mA b‐mediated target cell deletion
LN Dahal, A Gadd, AD Edwards… - Scandinavian …, 2018 - Wiley Online Library
Toll‐like receptors (TLR) are critical mediators of the immune system with their activation
linked to infection, inflammation and the pathogenesis of immune diseases including …
linked to infection, inflammation and the pathogenesis of immune diseases including …
EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I–associated adult …
Imiquimod is an immune response modifier currently used as a topical treatment of genital
warts, basal cell carcinoma, cutaneous metastasis of malignant melanoma, and vascular …
warts, basal cell carcinoma, cutaneous metastasis of malignant melanoma, and vascular …
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
BACKGROUND: Mycosis fungoides and Sézary syndrome are a class of lymphomas of skin-
trafficking T cells, and they are the most common forms of cutaneous T-cell lymphoma …
trafficking T cells, and they are the most common forms of cutaneous T-cell lymphoma …